ziprasidone has been researched along with leflunomide in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duncton, MA; Emerling, DE; Kelly, MG; Nguyen, MT; Vincent, F | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Clement, B; Indorf, P; Kubitza, C; Kunze, T; Scheidig, AJ | 1 |
1 review(s) available for ziprasidone and leflunomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for ziprasidone and leflunomide
| Article | Year |
|---|---|
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
Topics: Amidohydrolases; Carbamates; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Piperazines; Stereoisomerism; Structure-Activity Relationship | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
Topics: Biological Assay; Humans; Inactivation, Metabolic; Metabolic Clearance Rate; Mitochondria; Mitochondrial Proteins; Oxidation-Reduction; Oxidoreductases; Oximes; Substrate Specificity | 2020 |